trending Market Intelligence /marketintelligence/en/news-insights/trending/NqymtbcsoMaFDoEGV0jv-Q2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Trump's drug czar pick Marino withdraws after outcry over weakening DEA

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Trump's drug czar pick Marino withdraws after outcry over weakening DEA

President Donald Trump disclosed in an Oct. 17 morning tweet that Rep. Tom Marino, R-Pa., was withdrawing his name from consideration as the director of National Drug Control Policy — the White House drug czar.

"Tom is a fine man and a great congressman," Trump added.

Marino came under fire after the Washington Post and CBS' "60 Minutes" revealed that the Pennsylvania congressman had pushed a bill through Congress that weakened the Drug Enforcement Administration's ability to rein in distributors selling opioids to rogue pharmacies.

There was a growing outcry from members of Congress for Marino to withdraw his name, including from Democrat Sen. Joe Manchin, whose home state of West Virginia has been plagued by the U.S. opioid crisis.

Manchin also introduced legislation that aims to repeal Marino's bill.

Trump told reporters Oct. 16 that he would review Marino's nomination. He also vowed to formalize his earlier declaration to make the opioid crisis a national emergency.